A 10-year-old girl with steroid-resistent Diamond-Blackfan anemia (DBA) developed agranulocytosis 9 weeks after initiating chelation with deferiprone 45 mg/kg daily (60% of recommended dose) in addition to her ordinary deferoxamine therapy. The blood counts, checked weekly, dropped markedly between weeks 8 and 9. She rapidly developed a septicemia and was admitted with high fever (40. We conclude that weekly neutrophil monitoring is not sufficient to avoid fatal agranulocytosis. We suggest that deferiprone is not prescribed to DBA patients, unless the clinical indications are particularly strong, and that the risk of agranulocytosis in thalassemia patients is considered carefully.
INTRODUCTION
In Diamond-Blackfan anemia (DBA), a pure red cell anemia with autosomal dominant inheritance with known linkage to chromosomes 19q13.2 (DBA1) and 8p23-22 (DBA2) [2] [3] [4] , most patients respond to corticosteroids but 15-20% are steroid-resistent already at diagnosis and this figure may increase over time [1] . For some steroid-resistent patients, hematopoietic stem cell transplant (HSCT) is a reasonable treatment but for many patients regular erythrocyte transfusions are required [1] .
Secondary hemochromatosis is a major medical problem in transfusion-dependent patients [1, 5] . In addition to the widely accepted chelating therapy with deferoxamine, oral chelating substances are now available, such as deferiprone and deferasirox reported to be beneficial alone or in combination with deferoxamine [6] [7] [8] [9] [10] [11] [12] . These studies have been facilitated by the T2* magnetic resonance imaging (MRI) technique [8, 13] .
Most drugs have side effects and it is important to be aware of them and their potential severity to properly weight pros and cons. Deferiprone is effective in reducing myocardial iron, but its value has also been disputed [14, 15] . Here we report a 10-year-old girl with DBA who died with agranulocytosis shortly after the introduction of deferiprone therapy.
RESULTS AND DISCUSSION

Case report
A 2-months old girl to healthy related parents was diagnosed with DBA (hemoglobin 27 g/L, WBC 14.1x10 9 /L, platelets 746x10 9 /L, reticulocytes 0.0% at admission). Bone marrow examination revealed an almost complete lack of erythropoiesis consistent with DBA. She had no external malformations; ultrasound of kidneys and skeletal survey were normal. In addition
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From to erythocyte transfusions she was administered prednisolone up to 4 mg/kg daily without any response. HSCT was considered but she had no matched related donor and an unrelated donor transplant was at that time not recommended [16] . Up to the age of 10 she was on a regular transfusion-chelating program with good compliance and ferritin levels typically between 1000-2000 microgram/L. A third prednisolone trial was not successful, neither was an attempt with cyclosporin A [17] . Audiometry, normal at age 4, revealed a severe left-sided sensorineural hearing deficiency at age 6, the cause of which could not be fully explained [18, 19] . HSCT was reconsidered several times, but not accepted [16] . Liver biopsies, (Ferriprox) 500 mg twice daily was added corresponding to 60% of the recommended dose, in an attempt to reduce side effects, and blood counts were meticulously monitored on a weekly basis (Table 1) . A secondary aim was to improve her quality of life. The parents were informed on the risk of agranulocytosis, the reason for the weekly blood count monitoring, and gave their consent to the therapy. Initially the deferiprone treatment was entirely successful but the 9 th week after initiating deferiprone her blood counts dropped markedly to ANC <0.1x10 9 /L, WBC 0.9x10 9 /L and platelets 164x10 9 /L; deferiprone administration was stopped promptly (Table 1) . However, the following day she had developed a sore throat, moderate cough and high fever (40. between these infiltrates the cellularity was around 30% with signs of fibrosis. In areas with low cellularity, mostly macrophages and in particular megakaryocytes were found.
Granulopoiesis and erythropoiesis was very scarce. The widely spread lymphoid infiltrates
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Bone marrow flow cytometry revealed that 72% of the cells were in the lymphocyte region, of these 86% were T-cells with signs of activation; 57% stained for T-cell markers and HLADR.
The CD4/CD8 ratio was 0.68. CD56+ cells were 21% and CD57+ cells 27%, the latter mostly CD8+CD28-. Furthermore, CD69+ T-cells were increased (14%), indicating activation.
CD34+ cells were 0.37% of all cells.
An updated review of PubMed (December 12, 2006) revealed one patient with DBA that developed agranulocytosis with deferiprone [20] . In the patient, a 28-year-old female, neutrophils reappeared after 17 days and normalized after 36 days. In addition, a 19-year-old male patient that developed neutropenia which was stable for one year but later progressed into a fatal aplastic anemia has been reported from Venezuela at a medical meeting [21] . It has previously been reported that a large proportion of steroid-refractory DBA patients develop moderate to severe generalized bone marrow hypoplasia over time [22] . Moreover, reduced clonogenic cell output in long-term culture-initiating cell assays, quantifying
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From multilineage primitive hematopoietic progenitors, also suggest that the underlying defect in steroid-refractory DBA not is limited to the erythroid lineage [22] . The bone marrow investigation in the present patient, with widely spread T-cell infiltrates consistent with signs of T-cell activation, suggests that immunological mechanisms may play a role in the development of the bone marrow hypoplasia in DBA. Thus, DBA patients may be more prone than thalassemia patients to develop deferiprone-associated agranulocytosis.
We conclude that since the agranulocytosis developed rapidly, weekly monitoring of blood counts during deferiprone therapy is not sufficient to avoid the development of persistent and potentially fatal agranulocytosis. Moreover, the rapid development of a prolonged agranulocytosis, despite administering only 60% of the recommended dose, suggest that this side effect may not be dose dependent. Since the development of agranulocytosis is not predictable and possibly not dose dependent, and since it is not avoidable despite meticulous blood count monitoring, we suggest that deferiprone is not prescribed to patients with DBA, or prescribed only if the clinical indications are particularly strong. Data on the risk of agranulocytosis in thalassemia was updated in 2003 [23] and additional information on deferiprone-associated agranulocytosis available through the manufacturer has, now, been presented (available through the website reported above). It is important that information regarding the risk of developing non-reversible agranulocytosis secondary to deferiprone, in particular in DBA patients, is widely distributed.
